Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Billin

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacyKaren A Evans, Barry G Shearer, David D Wisnoski, et al.
Plos One|August 20, 2015
Genetic Ablation of CD38 Protects against Western Diet-Induced Exercise Intolerance and Metabolic InflexibilityShian-Huey Chiang, W Wallace Harrington, Guizhen Luo, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
Molecular Endocrinology (Baltimore, Md.)|December 8, 2009
ERRgamma regulates cardiac, gastric, and renal potassium homeostasisWilliam A Alaynick, James M Way, Stephanie A Wilson, et al.
Skeletal Muscle|November 15, 2018
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Skeletal Muscle|December 12, 2018
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacyKaren A Evans, Barry G Shearer, David D Wisnoski, et al.
Plos One|August 20, 2015
Genetic Ablation of CD38 Protects against Western Diet-Induced Exercise Intolerance and Metabolic InflexibilityShian-Huey Chiang, W Wallace Harrington, Guizhen Luo, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.
Molecular Endocrinology (Baltimore, Md.)|December 8, 2009
ERRgamma regulates cardiac, gastric, and renal potassium homeostasisWilliam A Alaynick, James M Way, Stephanie A Wilson, et al.
Skeletal Muscle|November 15, 2018
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Skeletal Muscle|December 12, 2018
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Hepatology (Baltimore, Md.)|June 10, 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASHJun Xu, Ya Wang, Mina Khoshdeli, et al.
Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.
Pageof 6